Home » KAP International Association Summit: Europe’s first major ketamine-assisted psychotherapy event comes to Barcelona in October 2026
, ,

KAP International Association Summit: Europe’s first major ketamine-assisted psychotherapy event comes to Barcelona in October 2026

Red neuronal luminosa converge en un nodo central, simbolizando la psicoterapia y Barcelona como epicentro

The Ketamine Research Foundation (KRF), a US-based non-profit and a world reference in ketamine research and training, together with Barcelona’s Clínica Synaptica, a pioneer in psychedelic medicine in Spain, have joined forces to launch the KAP International Association: a global initiative that makes Barcelona the European epicentre of ketamine-assisted psychotherapy (KAP) and will hold its first major international gathering from 15 to 23 October 2026 under the name The Complete KAP Experience.

Registration and sponsorship at https://www.clinicasynaptica.com/en/kap/

What KAP is and why it matters now

Ketamine-Assisted Psychotherapy (KAP) is the first psychedelic psychotherapy legally available in the world. It combines the clinical administration of ketamine — the only medicine with psychoactive and psychedelic properties currently legal for therapeutic use — with structured psychotherapeutic support in three phases: preparation, guided session and later integration.

The KRF has spent more than a decade documenting its results in the US and Canada, where it has trained more than 1,100 health professionals in psychedelic psychotherapy. Its scope covers conditions such as treatment-resistant depression, anxiety disorders, PTSD, chronic pain, complicated grief and suicidal ideation; precisely the same conditions that Clínica Synaptica treats at its centre on Carrer Trafalgar in Barcelona, recognised as the first in Spain specialising in psychedelic medicine.

The therapeutic mechanism of ketamine rests on its ability to induce increased neural plasticity and altered states of consciousness that allow the patient to dissolve deep cognitive and emotional blocks. It is not a treatment for everyone or a substitute for conventional psychotherapy, but a complementary tool with growing scientific evidence for those who do not respond to the usual approaches.

The alliance that makes the KAP International Association possible

The KAP International Association was born from a formal collaboration between two organisations that have spent years building the field from their respective sides of the Atlantic.

The Ketamine Research Foundation, founded and led by Dr Phil Wolfson, is the longest-standing and best-known non-profit in the sector. Wolfson, a psychiatrist and psychotherapist with decades of experience in psychedelic research — from the early days of MDMA to the systematic development of KAP — is regarded as one of the fathers of this discipline. The KRF has built the world’s most complete bibliographic library on ketamine, has led multicentre clinical trials and has set the clinical practice guidelines and ethical standards that now guide the sector internationally. From San Francisco, the foundation has gradually extended its training network beyond the US, with a particular interest in Europe.

Clínica Synaptica, led by Òscar Parés as CEO, Dr Joan Obiols as medical director and José Carlos Bouso as scientific director — a specialist in transcultural psychiatry — is the European node of that expansion. From Barcelona, the clinic has treated patients of many nationalities, takes an active part in research with universities such as the UOC, the University of Valencia and the Catholic University of Porto, and also offers consultancy to other professionals who want to set up their own centres. Its clinical team — with figures such as Estefanía Moreno, Irene Pérez and Marta Martín — has integrated the KAP model developed by the KRF, adapting it to the European regulatory and cultural context.

The convergence of the two institutions is not new: in 2024 they jointly organised the first edition of KAP training in Barcelona, with notable success, and in 2025 they repeated it with a second edition structured on two levels. The KAP International Association is the natural next step: scaling that collaboration into an international association format, with a view to permanence and growth.

The Complete KAP Experience: the October 2026 programme

The Barcelona event from 15 to 23 October 2026 is organised in two complementary blocks, aimed at mental health and chronic pain professionals from around the world:

Level 1 — Advanced residential training after the Summit (19 to 23 October, on the outskirts of Barcelona). An intensive five-day residential programme, with accommodation and meals included, led by Phil Wolfson, Marc Aixalà, Audra Micallef and the Clínica Synaptica team. Designed exclusively for professionals with prior experience, the training combines guided sessions, holotropic breathwork and integrative practices inspired by the programmes of the US Ketamine Research Foundation (KRF). Places are limited to 17 participants and require a selection process before registration is confirmed.

Level 2 —Advanced experiential exchange (second week, on the outskirts of Barcelona). A five-day experiential retreat in a retreat house in a natural setting, just over an hour from Barcelona. Combining holotropic breathwork, integrative practices and guided sessions in groups and in pairs, this module — inspired by the seminars the KRF has been running in the US for a decade — is being held in Europe for the first time. The aim is for professionals not only to acquire tools but to experience them from the inside, consolidating their understanding of KAP’s transformative potential.

The line-up of speakers brings together some of the most relevant figures in the field worldwide: Phil Wolfson, creator of KAP and executive director of the Ketamine Research Foundation; Celia Morgan, a researcher at the University of Exeter with 25 years of studying ketamine; Christopher Timmermann, a neuroscientist and co-director of the UCL Centre for Consciousness Science; Lisa Gold, a specialist in relational KAP and creator of the Soul Surfing method; Lowan Stewart, an emergency physician and co-founder of the first public ketamine treatment units in Scandinavia; Ron Siegel, professor of Psychology at Harvard Medical School; José Carlos Bouso, scientific director of Clínica Synaptica and one of the leading references in psychedelic research in Spain; and Marc Aixalà, a psychologist specialising in psychedelic integration and holotropic breathwork.

Barcelona, European capital of psychedelic medicine

The choice of Barcelona is no coincidence. The city brings together a unique combination of factors: an advanced clinical and university ecosystem, a regulatory framework that allows work with ketamine under medical prescription, and an international profile that makes it a natural gateway for European, Latin American and other professionals who want to bring KAP into their practice.

For Òscar Parés, CEO of Clínica Synaptica, this training “marks a turning point for mental health in Europe”. For Phil Wolfson, the aim is clear: “to empower professionals to implement KAP ethically, drawing on models proven in the US”.

In this sense, the KAP International Association represents much more than a training programme: it is the institutional infrastructure Europe needs to develop this discipline with the rigour, ethics and coherence it deserves.

Keep reading

Funded by the European Union - NextGenerationEURecovery, Transformation and Resilience Plan (Spain)

Funded by the European Union – NextGenerationEU